Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck

(2015) Alexander Hoellein et al.   Oncotarget

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1

(2012) Sean Vance et al.   CELL CYCLE

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

(2011) Kurtis D. Davies et al.   CANCER BIOLOGY & THERAPY

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

Unleashing Chk1 in cancer therapy

(2011) Laura Carrassa et al.   CELL CYCLE

Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

(2011) A. Hoglund et al.   CLINICAL CANCER RESEARCH

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication

(2011) C. S. Sorensen et al.   NUCLEIC ACIDS RESEARCH

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer

(2011) E. Tili et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

(2011) K. A. Cole et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Targeting the checkpoint kinase Chk1 in cancer therapy

(2010) Callie Merry et al.   CELL CYCLE

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase

(2010) Halfdan Beck et al.   JOURNAL OF CELL BIOLOGY

Down-Regulation of Wee1 Kinase by a Specific Subset of microRNA in Human Sporadic Pituitary Adenomas

(2010) Henriett Butz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas

(2010) J Bartkova et al.   ONCOGENE

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

(2009) Clark C Chen et al.   Molecular Cancer

Dealing with DNA damage: Relationships between checkpoint and repair pathways

(2009) Daniël O. Warmerdam et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis

(2009) S. Peddibhotla et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

An Oncogene-Induced DNA Damage Model for Cancer Development

(2008) T. D. Halazonetis et al.   SCIENCE